ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARTV vs CGEN // OPERATING MARGIN

Artiva Biotherapeutics Inc. (NASDAQ) VS. Compugen Ltd. (NASDAQ) • 15-METRIC TALLY: ARTV 1 — CGEN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARTV VS. CGEN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARTV CGEN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 87.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 CGEN /roic <GO>
EV/EBITDA & P/E Valuation — 3.2x — TIE /valuation <GO>
Free Cash Flow Yield — 16.24% — TIE /fcf-yield <GO>
Operating Margin ACTIVE — 43.10% — TIE /operating-margins <GO>
Net Profit Margin — 48.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — 161.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.03 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 CGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 20.6 41.1 -20.49 CGEN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 4.6x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $206.8M $193.0M $13.9M ARTV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARTV REV CGEN REV ARTV GROSS % CGEN GROSS % ARTV FCF CGEN FCF
FY 2025 $0 $72.8M — 87.3% -$79.3M $31.3M
FY 2024 $251.0K $27.9M — 71.5% -$55.7M $49.5M
FY 2023 $32.9M $33.5M — — -$47.4M -$35.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARTV // BETA —
CGEN // BETA —